Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
New drugs which may have the potential to stop faulty brain cells dying and slow down the progression of Parkinson's, have been identified by scientists in a pioneering study which is the first of its kind.
Experts from the world leading Sheffield Institute for Translational Neuroscience (SITraN) conducted a large scale drugs trial in the lab using skin cells from people with this progressive neurological condition which affects one in every 500 people in the UK.
The researchers tested over 2,000 compounds to find out which ones could make faulty mitochondria work normally again.
Mitochondria act as the power generators in all cells of our body, including the brain. Malfunctioning mitochondria are one of the main reasons why brain cells die in Parkinson's.
One of the promising medications identified though the research is a synthetic drug called ursodeoxycholic acid (UDCA).
This licenced drug has been in clinical use for several decades to treat certain forms of liver disease which means that researchers will be able to immediately start a clinical trial to test its safety and tolerability in people with Parkinson's.
This will discover the optimum dose to ensure that enough of the drug reaches the part of the brain where Parkinson's develops.
Based on this information, larger randomized controlled trials can be carried out to assess the potential of UDCA to treat Parkinson's.
The extensive drug screen, which took over five years to complete, was funded by leading research charity Parkinson's UK, and was carried out in collaboration with the University of Trondheim, Norway.
Dr Oliver Bandmann, Reader in Neurology at SITraN, said: "Parkinson's is so much more than just a movement disorder.
"The best treatments currently available only improve some of the symptoms, rather than tackle the reason why Parkinson's develops in the first place, so there is a desperate need for new drug treatments which could actually slow down the disease progression".
"We are hopeful that this group of drugs can one day make a real difference to the lives of people with Parkinson's".
The results of the ground breaking study were published in the leading Neuroscience journal BRAIN on 2 Septmber 2013.
Dr Kieran Breen, Director of Research and Innovation at Parkinson's UK commented: "This is a really exciting time for Parkinson's research. For the first time, we are starting to identify drugs that will treat the Parkinson's - possibly slow down or halt its progression - rather than just the symptoms.
"This will bring us closer to our ultimate goal of a cure for Parkinson's. We look forward to working closely with Dr Bandmann to develop this treatment".
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Parkinson's Disease category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
University of Sheffield. "Ground breaking research identifies promising drugs for treating Parkinson's - including the licenced drug ursodeoxycholic acid." Medical News Today. MediLexicon, Intl., 6 Sep. 2013. Web.
11 Dec. 2013. <http://www.medicalnewstoday.com/releases/265664>
University of Sheffield. (2013, September 6). "Ground breaking research identifies promising drugs for treating Parkinson's - including the licenced drug ursodeoxycholic acid." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/265664.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.